UroGen Pharma Ltd
URGN
40.70
-0.73
-1.76%
UroGen Pharma Ltd
US · URGN
#2773 by market cap
Listed 2017
40.70
-0.73
-1.76%
Live - 5344 symbols - heartbeat 11s ago
· 2026-10-08 05:49
Pre-market
40.90
+0.49%
After-hours
40.50
-0.49%
- Market cap
- 1.99B
- P/E (TTM)i
- -20.66
- P/Bi
- -15.02
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on URGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.47, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +21.45% YoY
Margins
- Gross margin
- 88.66%
- Operating margin
- -113.73%
- Net margin
- -139.81%
Key ratios & quality
- Altman Z-Scorei
- -3.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.13M | 18.00K | 11.80M | 48.04M | 64.36M | 82.71M | 90.40M | 109.79M |
| Gross profit | -675.00K | 18.00K | 10.79M | 42.89M | 56.70M | 73.35M | 81.52M | 97.34M |
| Selling & admin expenses | 39.57M | 60.20M | 90.22M | 87.54M | 82.84M | 93.27M | 121.15M | 155.10M |
| Research & development | 36.93M | 49.30M | 47.31M | 47.64M | 52.91M | 45.61M | 57.15M | 67.11M |
| Operating profit | -77.18M | -109.48M | -126.74M | -92.29M | -79.04M | -65.54M | -96.78M | -124.86M |
| Pretax profit | -75.53M | -105.15M | -125.11M | -109.37M | -108.03M | -98.32M | -124.04M | -153.42M |
| Tax | 125.00K | 0 | 3.37M | 1.45M | 1.76M | 3.92M | 2.83M | 78.00K |
| Net profit | -75.66M | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M | -126.87M | -153.49M |
| Basic EPS | -5 | -5 | -6 | -5 | -5 | -4 | -3 | -3 |
| Diluted EPS | -4.80 | -5.12 | -5.90 | -4.96 | -4.81 | -3.55 | -2.96 | -3.19 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 20.25M | 24.22M | 27.48M | 37.84M | 50.96M | 72.46M |
| Gross profit | 17.92M | 20.67M | 24.20M | 34.55M | 46.82M | 65.88M |
| Selling & admin expenses | 34.97M | 43.20M | 37.58M | 39.35M | 51.49M | 48.44M |
| Research & development | 19.87M | 18.91M | 14.01M | 14.31M | 15.60M | 17.34M |
| Operating profit | -36.91M | -41.45M | -27.39M | -19.12M | -20.26M | 111.00K |
| Pretax profit | -43.45M | -48.93M | -34.40M | -26.64M | -28.35M | -8.72M |
| Tax | 392.00K | 1.02M | -1.05M | -275.00K | -4.77M | 5.63M |
| Net profit | -43.84M | -49.94M | -33.35M | -26.36M | -23.57M | -14.35M |
| Basic EPS | -1 | -1 | -1 | -1 | 0 | 0 |
| Diluted EPS | -0.92 | -1.05 | -0.69 | -0.54 | -0.47 | -0.28 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 102.24M | 148.63M | 115.62M | 114.39M | 128.91M | 169.19M | 276.14M | 186.02M |
| Cash & ST investments | 101.32M | 147.08M | 102.02M | 89.14M | 99.96M | 136.97M | 236.69M | 120.46M |
| Inventory | -- | 0 | 1.96M | 4.83M | 4.33M | 5.67M | 9.23M | 16.46M |
| Total assets | 103.56M | 202.39M | 122.01M | 119.75M | 135.62M | 178.31M | 285.71M | 200.46M |
| Total current liabilities | 13.47M | 19.48M | 21.44M | 22.38M | 23.92M | 31.21M | 45.95M | 46.42M |
| Short-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | 97.54M | 98.55M | 121.73M | 122.21M |
| Total liabilities | 13,465,000.00 | 22,086,000.00 | 25,650,000.00 | 111,333,000.00 | 224,980,000.00 | 243,523,000.00 | 294,514,000.00 | 305,929,000.00 |
| Total equity | 90.09M | 180.30M | 96.36M | 8.41M | -89.36M | -65.21M | -8.80M | -105.47M |
| Retained earnings | -122.87M | -228.02M | -356.50M | -467.32M | -577.10M | -679.35M | -806.22M | -959.72M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 237.18M | 196.87M | 168.55M | 186.02M | 237.46M | 235.43M |
| Cash & ST investments | 195.89M | 156.95M | 127.03M | 120.46M | 140.27M | 107.98M |
| Inventory | 7.59M | 7.13M | 8.34M | 16.46M | 20.92M | 24.59M |
| Total assets | 247.62M | 208.72M | 185.05M | 200.46M | 253.69M | 252.59M |
| Total current liabilities | 42.00M | 47.55M | 42.24M | 46.42M | 50.64M | 61.92M |
| Short-term debt | -- | -- | -- | -- | -- | 2.10M |
| Long-term debt | 122.11M | 122.51M | 122.11M | 122.21M | 189.53M | 188.73M |
| Total liabilities | 294,076,000.00 | 302,093,000.00 | 300,454,000.00 | 305,929,000.00 | 377,943,000.00 | 384,986,000.00 |
| Total equity | -46.46M | -93.38M | -115.41M | -105.47M | -124.25M | -132.40M |
| Retained earnings | -850.07M | -900.01M | -933.35M | -959.72M | -983.29M | -997.64M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -37.33M | -71.02M | -105.89M | -84.89M | -87.56M | -76.38M | -96.77M | -162.44M |
| Depreciation & amortization | 417.00K | 1.32M | 2.04M | 1.77M | 1.82M | 1.71M | 1.19M | 2.41M |
| Free cash flow | -37.89M | -71.34M | -107.10M | -85.64M | -87.81M | -76.57M | -97.06M | -162.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 64.24M | 161.66M | 15.85M | -- | 0 | 67.36M | 151.17M | 39.80M |
| Ending cash balance | 101.57M | 50.21M | 54.09M | 45.59M | 56.22M | 95.82M | 173.06M | 112.10M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -42.02M | -39.83M | -42.27M | -38.33M | -45.32M | -33.01M |
| Depreciation & amortization | 497.00K | 596.00K | 639.00K | 679.00K | 652.00K | 668.00K |
| Free cash flow | -42.07M | -39.97M | -42.36M | -38.34M | -45.37M | -33.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 4.00K | -- | -- | 31.83M | 0 | -- |
| Ending cash balance | 105.11M | 93.99M | 91.39M | 112.10M | 111.30M | 80.46M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -95.40 | -77.77 | -92.88 | -211.55 | -- | -- | -- | -- |
| ROA %i | -84.48 | -68.73 | -79.22 | -91.68 | -85.98 | -65.14 | -54.68 | -63.14 |
| ROIC %i | -97.12 | -79.65 | -92.56 | -208.29 | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -66.13 | -68.06 | -104.95 | -- | -- | -- | -- |
| EBIT margin %i | -6,842.20 | -608,211.11 | -1,074.15 | -192.11 | -154.75 | -101.08 | -123.37 | -125.76 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.59 | 7.63 | 5.39 | 5.11 | 5.39 | 5.42 | 6.01 | 4.01 |
| Quick ratioi | 7.52 | 7.55 | 5.09 | 4.51 | 4.71 | 4.88 | 5.59 | 3.31 |
| Debt / assetsi | 0.00 | 1.29 | 1.23 | 0.33 | 73.09 | 55.74 | 43.19 | 64.02 |
| LT debt / equityi | -- | 1.44 | 1.55 | 4.73 | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -11.80 | -5.68 | -8.91 | -9.00 |
| Revenue CAGR (3Y) %i | -- | -89.91 | 13.09 | 249.22 | 1,429.12 | 91.39 | 23.46 | 19.49 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -61.77 | -63.18 | -67.62 | -63.14 | -53.15 | -42.33 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -131.84 | -144.32 | -151.45 | -125.76 | -87.44 | -43.39 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.65 | 4.14 | 3.99 | 4.01 | 4.69 | 3.80 |
| Quick ratioi | 5.13 | 3.71 | 3.47 | 3.31 | 3.86 | 3.18 |
| Debt / assetsi | 50.46 | 60.33 | 69.36 | 64.02 | 76.94 | 77.65 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -8.56 | -9.18 | -9.45 | -9.00 | -7.95 | -5.05 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Zusduri is the largest reported line at 69.60% of revenue, across 2 reported segments.
- Jelmyto follows at 30.40%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Zusduri69.60%
Jelmyto30.40%
Quote time 2026-10-08 05:49:07 · For reference only, not investment advice and not tailored to your situation.